BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 29043469)

  • 1. E3 ubiquitin ligases in cancer and implications for therapies.
    Wang D; Ma L; Wang B; Liu J; Wei W
    Cancer Metastasis Rev; 2017 Dec; 36(4):683-702. PubMed ID: 29043469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.
    Uchida C; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting E3 ubiquitin ligases for cancer therapy.
    Sun Y
    Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RBR E3 ubiquitin ligases in tumorigenesis.
    Wang P; Dai X; Jiang W; Li Y; Wei W
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):131-144. PubMed ID: 32442483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
    Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
    Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
    Liu L; Wong CC; Gong B; Yu J
    Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Insights Into E3 Ubiquitin Ligase in Cancer Chemoresistance.
    Yang L; Chen J; Huang X; Zhang E; He J; Cai Z
    Am J Med Sci; 2018 Apr; 355(4):368-376. PubMed ID: 29661351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cullin-RING Ligases as attractive anti-cancer targets.
    Zhao Y; Sun Y
    Curr Pharm Des; 2013; 19(18):3215-25. PubMed ID: 23151137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of a HOIP/E2~ubiquitin complex reveals RBR E3 ligase mechanism and regulation.
    Lechtenberg BC; Rajput A; Sanishvili R; Dobaczewska MK; Ware CF; Mace PD; Riedl SJ
    Nature; 2016 Jan; 529(7587):546-50. PubMed ID: 26789245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
    Kitagawa K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RBR E3 ubiquitin ligases: new structures, new insights, new questions.
    Spratt DE; Walden H; Shaw GS
    Biochem J; 2014 Mar; 458(3):421-37. PubMed ID: 24576094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E3 ubiquitin ligases as cancer targets and biomarkers.
    Sun Y
    Neoplasia; 2006 Aug; 8(8):645-54. PubMed ID: 16925947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HECT-Type E3 Ubiquitin Ligases in Cancer.
    Bernassola F; Chillemi G; Melino G
    Trends Biochem Sci; 2019 Dec; 44(12):1057-1075. PubMed ID: 31610939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of E3 ubiquitin ligases in gastric cancer.
    Hou YC; Deng JY
    World J Gastroenterol; 2015 Jan; 21(3):786-93. PubMed ID: 25624711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme-substrate relationships in the ubiquitin system: approaches for identifying substrates of ubiquitin ligases.
    O'Connor HF; Huibregtse JM
    Cell Mol Life Sci; 2017 Sep; 74(18):3363-3375. PubMed ID: 28455558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the ubiquitin pathway for cancer treatment.
    Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
    Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HECT family of E3 ubiquitin ligases: multiple players in cancer development.
    Bernassola F; Karin M; Ciechanover A; Melino G
    Cancer Cell; 2008 Jul; 14(1):10-21. PubMed ID: 18598940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A patent review of the ubiquitin ligase system: 2015-2018.
    Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
    Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted modulation of E3 ligases using engineered ubiquitin variants.
    LeBlanc N; Mallette E; Zhang W
    FEBS J; 2021 Apr; 288(7):2143-2165. PubMed ID: 32867007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.